Loading...
XNYS
ABT
Market cap218bUSD
Dec 04, Last price  
125.40USD
1D
0.09%
1Q
-5.67%
Jan 2017
226.48%
Name

Abbott Laboratories

Chart & Performance

D1W1MN
XNYS:ABT chart
P/E
16.29
P/S
5.20
EPS
7.70
Div Yield, %
1.75%
Shrs. gr., 5y
-0.37%
Rev. gr., 5y
5.63%
Revenues
41.95b
+4.59%
22,337,808,00022,476,322,00025,914,238,00029,527,552,00030,765,000,00035,167,000,00038,851,000,00039,874,000,00021,848,000,00020,247,000,00020,405,000,00020,853,000,00027,390,000,00030,578,000,00031,904,000,00034,608,000,00043,075,000,00043,653,000,00040,109,000,00041,950,000,000
Net income
13.40b
+134.18%
3,372,065,0001,716,755,0003,606,314,0004,880,719,0005,745,838,0004,626,172,0004,728,000,0005,963,000,0002,576,000,0002,284,000,0004,423,000,0001,400,000,000477,000,0002,368,000,0003,687,000,0004,495,000,0007,071,000,0006,933,000,0005,723,000,00013,402,000,000
CFO
8.56b
+17.86%
5,174,416,0005,329,241,0005,183,843,0007,344,191,0007,275,160,0008,735,981,0008,970,077,0009,314,401,0003,324,000,0003,675,000,0002,966,000,0003,203,000,0005,570,000,0006,300,000,0006,136,000,0007,901,000,00010,533,000,0009,581,000,0007,261,000,0008,558,000,000
Dividend
Oct 15, 20240.55 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
IPO date
Mar 01, 1937
Employees
115,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT